Skip to content
Screener

Amphastar Pharmaceuticals AMPH Finished Pharmaceutical Products — Goodwill

Similar metrics at other companies

Opko Health logo
OPKPharmaceutical — Goodwill
$318.07M-0.8%
Baxter International logo
BAXPharmaceuticals — Goodwill
$569M+2.2%
Bausch + Lomb logo
BLCOPharmaceuticals — Goodwill
$720M-3.7%
McKesson logo
MCKNorth American Pharmaceutical — Goodwill
$2.76B
Cardinal Health, Inc. logo
CAHPharmaceutical and Specialty Solutions — Goodwill
$9.7B+22.1%
Cadre Holdings logo
CDREProducts — Goodwill
$231.29M+34.6%

Other financials

Income statement

See full
Revenue$183.9M+5.4%
Gross profit$93.5M+8.1%
Operating income$39.7M-5.8%
Net income$30.3M-2.2%
EPS (diluted)$0.67+4.7%

Balance sheet

See full
Cash & equivalents$223.6M+19.1%
Total debt$688.5M+5.0%
Total equity$445.5M
Total assets$1.7B+8.0%

Cash flow

See full
Operating cash flow$51.3M+44.2%
CapEx$8.6M-18.7%
Free cash flow$42.7M+70.7%

Valuation

See full
Market cap$863.95M-32.1%
Enterprise value$1.33B-23.6%
P/E11×+1.6×
P/S1.2×-0.6×

Profitability

See full
Gross margin47.7%-2.2pp
Operating margin15.7%-9.5pp
Net margin10.8%-7.9pp
FCF margin20.9%+5.4pp

Returns & leverage

See full
Return on equity14.7%
Debt / equity0.2×
Current ratio2.4×-0.9×

Where this comes from

Reported directly by Amphastar Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:Goodwill.

The source filing: Amphastar Pharmaceuticals’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:50 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001297184-26-000047
Line itemWeighted-Average / Life (Years)Original CostAccumulated / AmortizationNet Book Value
Land-use rights392,5409801,560
Other intangibles72,4436251,818
Subtotal23690,81975,522615,297
Indefinite-lived intangible assets
Trademark*29,22529,225
Goodwill*3,3113,311
Subtotal*32,53632,536
As of June 30, 2026*$723,355$75,522$647,833

Item 1. Financial Statements (unaudited)

FAQ

What is Amphastar Pharmaceuticals's finished pharmaceutical products — goodwill?
Amphastar Pharmaceuticals (AMPH) reported finished pharmaceutical products — goodwill of $3.31M in Q2 2026.
How has Amphastar Pharmaceuticals's finished pharmaceutical products — goodwill changed year-over-year?
Amphastar Pharmaceuticals's finished pharmaceutical products — goodwill decreased by 2.5% year-over-year, from $3.4M to $3.31M.
What is the long-term trend for Amphastar Pharmaceuticals's finished pharmaceutical products — goodwill?
Over 4 years (2021 to 2025), Amphastar Pharmaceuticals's finished pharmaceutical products — goodwill has grown at a -1.7% compound annual growth rate (CAGR), from $14.33M to $13.36M.
What does finished pharmaceutical products — goodwill mean?
This represents the intangible asset value recorded when the cost of an acquired business unit exceeds the fair value of its identifiable net assets. It reflects the premium paid for expected future economic benefits, such as brand reputation, customer relationships, and proprietary technology within the finished pharmaceutical products segment.

Ask your AI about Amphastar Pharmaceuticals's finished pharmaceutical products — goodwill.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude